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CLINICAL PRACTICE • Clinical update
BACKGROUND
Since the last series of guidelines on the
management of osteoporosis from
Osteoporosis Australia was published in
Australian Family Physician (October
2002), there have been further advances in
our understanding of the treatment
involved in both the prevention of bone
loss and the management of established
osteoporosis.
OBJECTIVE
This article provides updated guidelines
for the management of postmenopausal
osteoporosis to assist general practitioners
identify those women at risk, and reviews
current treatment strategies. 
DISCUSSION
Osteoporosis and its associated problems
are major health concerns in Australia,
especially with an aging population. While
important principles of management are
still considered to be maximising peak
bone mass and preventing
postmenopausal bone loss, new clinical
trial data about drugs such as the
bisphosphonates, raloxifene and oestrogen
have recently become available and the
relative role of various agents is gradually
becoming clearer. The use of long term
hormone therapy has mixed risks and
benefits that requires individual patient
counselling.
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Osteoporosis is defined as a compromise in
bone strength, related to a decrease in bone
mass/density and an alteration in bone quality
(architecture, microcrack and microdamage
accumulation, mineralisation, bone turnover
and collagen quality) resulting in osteofragility
fractures.1 Clinically, osteoporosis is synony-
mous with low bone density. An osteoporotic
fracture is one that occurs with minimal or no
trauma, typically defined as a fall from standing
height or less. 
In 2001, approximately 2 million Australians
were estimated to be affected by osteoporosis,
three-quarters of whom were women. This
condition is more prevalent than hyperlipi-
daemia and incurs more years of healthy life
lost than Parkinson disease, cervical cancer or
rheumatoid arthritis. The total cost burden of
osteoporosis was estimated at $7.4 billion per
year.2 The health burden of osteoporosis will
only increase as our population ages.3 The risk
of developing osteoporosis is increased by




A relevant history should include age of menar-
che, age of menopause, smoking history, prior
fracture, family history of osteoporosis and
medical conditions listed in Table 2. Routine
examination of postmenopausal women should
include measurement of height, with a 2 cm
height decrease over 3 years suspicious for
osteoporosis.4 Assessment for kyphosis may
also be used, although in many elderly women
this spinal deformity may occur due to severe
spondylosis or scoliosis.5
Investigations
Dual energy X-ray absorptiometry (DEXA)
remains the gold standard for the diagnosis of
osteoporosis. Other investigations such as plain
X-ray and blood tests may assist with diagnosis,
management and follow up. 
DEXA
All postmenopausal women sustaining a low
trauma fracture should be considered for bone
densitometry because of the high likelihood of
having osteopaenia/osteoporosis.
Dual energy X-ray absorptiometry mea-
sures a patient’s bone mineral density (BMD)
to help predict fracture risk. It has a reported
precision (reproducibility) in research studies
of about 1.0–1.5% at the spine and about 3%
at the proximal femur. In day-to-day practice
compared with research studies precision may
be somewhat less (see Monitoring therapy).
Postmenopausal women lose bone at a rate of
approximately 1–2% per year, therefore bien-
nial scans are generally adequate. In patients
who are likely to have increased bone loss (eg.
glucocorticoid treatment), more frequent
scans may be indicated.6
Bone mineral density is reported both as
an absolute value and in terms of a ‘t-score’,
which represents the number of standard
deviations (SD) from the young normal mean
BMD (Table 3). For every one SD decrease in
BMD (ie. a t-score reduction by one), the rela-
tive risk of fracture approximately doubles.7
Currently, total hip BMD is most commonly
used to predict overall fracture risk, as proxi-
mal femoral measurements are less affected
by osteoarthritis which can falsely elevate
spine BMD values. The z-score is the number
of standard deviations from population mean
for age (ie. age matched). As t-scores can
vary between different types of DEXA
machines, the Australian and New Zealand
Bone and Mineral Society is attempting to
standardise reporting by use of the Geelong
Osteoporosis Study reference population.8
Doctors should encourage DEXA  providers
to report their results using this reference
population.
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Table 1. Factors associated with increased risk of osteoporosis
• Increasing age
• Menopause (especially premature)
• Family history of osteoporosis
• Previous low trauma fracture
• Medical conditions (Table 2)
• Low calcium intake
• Low body weight (defined as BMI <20)
• Eating disorders associated with decreased weight
• Immobilisation
• Lifestyle factors including smoking, alcohol, lack of exercise or excessive exercise
Table 2. Medical conditions associated with increased risk of osteoporosis
• Prolonged glucocorticoid therapy
• Conditions associated with excess glucocorticoid secretion
• Amenorrhoea lasting more than 6 months before the age of 45 years
• Primary hyperparathyroidism
• Chronic liver disease
• Chronic renal disease
• Malabsorption (eg. coeliac disease)
• Rheumatoid arthritis and other inflammatory arthropathies (eg. ankylosing   
spondylitis)
• Conditions associated with thyroxine excess
NB: A Medicare rebate is available for bone densitometry in these situations
In older women, fracture risk is dependent
on both age and BMD. That is, a woman 70
years of age with a BMD t-score value of –2.5
or less may have the same risk of fracture as a
woman 50–60 years of age with a BMD t-score
value of –3 to –4. 
Plain X-ray
Plain films are used commonly to diagnose
peripheral fractures, but also play an important
role in the diagnosis of clinical (ie. painful) and
asymptomatic (morphometric) vertebral frac-
tures. A loss of greater than 20% of vertebral
height is diagnostic of a vertebral fracture and in
the absence of a history of trauma, suggests
osteoporosis. In women over 65 years of age,
spinal X-ray becomes important when normal
bone densitometry may be misinterpreted as a
result of spondylosis, vertebral compression or
extra-skeletal calcification. 
Blood tests
Blood tests are usually normal, but may be indi-
cated to exclude other specific medical
conditions (Table 2). This is particularly 
important where the z-score is <–1.5 on 
bone densitometry. Typical investigations 
might include:
• full blood count (FBC)
• erythrocyte sedimentation rate (ESR)
• calcium 
• creatinine
• total alkaline phosphatase and albumin
• thyroid stimulating hormone (TSH)
• protein electrophoresis (EPP)
• antitissue transglutaminase antibody (TTG)
or anti-endomysial antibody 
• parathyroid hormone (PTH)
• 25 hydroxy vitamin D. 
Biochemical markers of bone remodelling
Serial biochemical markers of bone turnover
can be measured in serum and urine and may
provide additional information for assessing
fracture risk. In longitudinal studies, markers of
high bone turnover such as serum bone gla-
protein (osteocalcin) or urinary crosslinks/
telopeptides have been shown to predict a
similar fracture risk as reductions in BMD mea-
sured by DEXA.9 In clinical practice, increased
bone turnover markers in the presence of a low
BMD would favour treatment of the patient.
Additionally, markers may be used to assess
the response to treatment and thus increase
therapy adherence.10 However, in clinical prac-
tice at primary care level they are rarely needed. 
Management of postmenopausal
osteoporosis and osteopaenia
Although osteoporosis is a common condition,
a cause should be identified if possible and the
specific disease processes treated appropri-
ately. Decisions to commence therapy should
take account of the patient’s age and t-score.
In general, interventions are indicated for
women with bone densities more than 2.5 SD
units below the young normal mean (t-score
<–2.5), with preventive measures to be consid-
ered before that level is reached. Accordingly,
the following intervention guidelines are sug-
gested (Figure 1):
• consider preventive measures in post-
menopausal women with significant
osteopaenia, ie. t-scores between –2.0 and
–2.5 as osteoporosis is likely with time. As
mild to moderate osteopaenia (t-score
between –1.0 and –2.0) in women aged
50–60 years will have a relatively low
absolute risk of fracture, it is more difficult to
justify treatment for potentially large
numbers of women in this category, and 
• strongly recommend treatment in post-
menopausal women with osteoporosis, ie.
BMD values lower than 2.5 SD below the
young normal mean (t-score <–2.5) and in
patients with osteoporotic fractures.
General lifestyle measures 
Recommendations apply to both optimisation
of bone strength as well as minimising fall risk.
These include lifestyle modification such as a
diet adequate in calories, protein, calcium, and
vitamin D, elimination of smoking and exces-
sive alcohol intake, and exercise and fall
prevention measures which may be beneficial
and prevent fractures. The optimal use of exer-
cise relies upon delivery of a sustained
adequate dose of the correct modality of exer-
cise to the target population while minimising
the risk of side effects.11
Medication
Although lifestyle prevention measures are
important, pharmaceutical agents may be rec-
ommended for the prevention of
postmenopausal bone loss. Randomised trials
have shown beneficial effects of potent bis-
912Reprinted from Australian Family Physician Vol. 33, No. 11, November 2004
Clinical practice: Guidelines for the management of postmenopausal osteoporosis for GPs
Any  fracture

















t-score –2 to –2.5
t-score <–2.5
Reassure and follow up in 2–5 years


















Figure 1. Intervention guidelines
NB: There are no data that intervention in women with mild to moderate osteopaenia (t-score –1.0–2.0) in the
absence of a prevalent fracture is beneficial in reducing the risk of subsequent osteoporotic fractures. Therapy
aimed at prevention of bone loss may be warranted in some clinical situations. The imperative to consider
intervention increases as the t-score decreases
Normal = t-score >–1
Osteopaenia = t-score between –1 
and –2.5
Osteoporosis = t-score <2.5
NB: WHO criteria apply to lumbar spine, hip and
forearm only 
Table 3. WHO definitions of low bone density for
postmenopausal women using DEXA
phosphonates, selective oestrogen receptor
modulators, oestrogen and tibolone in preven-
tion of postmenopausal bone loss.12–15 As most
of the controlled trials of antiresorptive agents
described below have used concomitant
calcium and vitamin D, it is appropriate to add
a calcium supplement to most therapies
except calcitriol. 
Bisphosphonates
Bisphosphonates are potent inhibitors of bone
resorption. Currently three bisphosphonates
are approved in Australia on the
Pharmaceutical Benefits Scheme (PBS)
(Authority required) for the treatment of estab-
lished osteoporosis in postmenopausal women
with fracture due to minimal trauma.
Alendronate and risedronate reduce the risk of
single, multiple and morphometric (asympto-
matic) vertebral fractures in women with
osteoporosis and one or more baseline verte-
bral fractures.16–19 Alendronate and risedronate
also reduce the risk of vertebral fractures by
50% in women who have osteoporosis
without a pre-existing vertebral fracture.17–18 The
risk reduction with potent bisphosphonates is
usually seen within the first 6–12 months.
Peripheral fracture rates are also reduced with
alendronate and risedronate in patients with a
prevalent vertebral fracture. Data for antihip
fracture efficacy are also available. In the alen-
dronate trials there was consistency in hip
fracture risk reduction, but hip fracture was not
a primary endpoint.17,20 In one risedronate trial in
which hip fractures were the primary endpoint,
there was a 40% reduction in hip fracture risk
among women aged 70–79 years with osteo-
porosis confirmed on DEXA (baseline t-score
<–3).21 In this study, women aged 80 years and
over who had largely been included because of
fall risk factors rather than low BMD did not
receive the same benefit. This highlights the
need to also address falls related factors in
women of advanced years.
The use of alendronate and risedronate has
been associated with dyspepsia, abdominal
pain and oesophageal ulceration and should be
prescribed with caution in patients with a
history of reflux oesophagitis or hiatus hernia.22
However, the overall risk of gastrointestinal
events with alendronate and risedronate is very
low and weekly bisphosphonates appear to
further reduce the risk of this side effect. 
Etidronate is used in a cyclical regimen for
osteoporosis, usually for 2 weeks every 3
months because it can result in mineralisation
defects if used continuously. A number of
smaller controlled trials with etidronate show
increases in lumbar spine bone density averag-
ing 5% over 2–3 years23 and suggest a 50%
reduction in vertebral fracture rate. Etidronate
has been associated with lower, but not
upper, gastrointestinal events. There appears
to be no risk of mineralisation defect with the
cyclical regimen. 
Bisphosphonates are polar (water soluble)
drugs and when taken orally the bioavailability is
low (<1%). Calcium should not be taken at the
same time of day as a bisphosphonate 
as it interferes with their absorption.
Bisphosphonates should also be taken at least
30 minutes before meals to allow adequate
absorption. In patients who are intolerant of oral
bisphosphonates, intravenous bisphosphonates
such as pamidronate and (more recently) zole-
dronate are sometimes used. Further studies
assessing antifracture efficacy with these regi-
mens are in progress. The increase in bone
mineral density that occurs with prolonged use
of bisphosphonates (>5 years) is maintained for
2–3 years after cessation.24 This does not occur
with hormone therapy, where BMD losses
commence soon after stopping the drug.25
Selective oestrogen receptor modulators
Raloxifene is a selective oestrogen receptor
modulator (SERM) which acts to decrease bone
resorption like oestrogen but without stimulat-
ing the breast or uterus. Lipid profiles are
improved and breast cancer incidence has been
reported to be reduced by 60–70% over 4
years.26 Controlled clinical trials with raloxifene
have shown modest increase in bone density,
although this is generally somewhat less than
that seen with bisphosphonates or oestrogen.
In women with prevalent vertebral fractures, a
36% reduction in vertebral fractures was noted
using a dose of 60 mg per day for 4 years. In
women without prevalent vertebral fractures,
the relevant risk reduction was greater (55%).27
Nonvertebral fractures were not reduced in the
main trial analysis for reasons that are unclear.
However, as a group, the patients were gener-
ally younger (mean age 66.5 years) than in
bisphosphonate studies, and hip fracture reduc-
tion was not considered as an endpoint in the
MORE study. In a posthoc analysis of the
MORE study, raloxifene resulted in a significant
14% reduction in peripheral fractures in a sub-
group of women who had radiographical
evidence of severe spinal deformities (>40%
compression).28 An increased risk of deep
venous thrombosis has been reported with
raloxifene users similar to that seen with
hormone therapy (HT) users.26 Treatment
should be stopped if patients are immobilised
for any prolonged period. Unlike HT, raloxifene
is not useful for the control of (and may
worsen) menopausal symptoms. Raloxifene is
available on the PBS (Authority required) for
established postmenopausal osteoporosis in
patients with fracture due to minimal trauma.
Raloxifene has also been shown to be effective
for prevention of postmenopausal bone loss
and should be considered as an alternative in
women unable to take oestrogen for this indica-
tion (no PBS listing for this purpose).29
Hormone therapy 
The role of long term postmenopausal HT in the
prevention and management of osteoporosis
remains controversial following publication of
the results of the Women’s Health Initiative
(WHI) study of combined oestrogen and prog-
estin therapy (cHT) and its study of oestrogen
alone therapy (ET).30,31 The WHI study initiated
these HT in women aged 50–79 years, many of
whom had cardiovascular risk factors. Women
with known osteoporosis were excluded, but
the WHI population was otherwise not
screened for osteoporosis risk (unlike the bis-
phosphonate and raloxifene studies). Despite
this, significant reductions in subsequent osteo-
porosis fractures were seen in both arms of the
trial. There were trends to other mixed risks
and benefits which differed between the two
therapeutic regimens. With so many endpoints,
there is controversy about the appropriate
adjusted confidence intervals; but the one risk
that clearly reached statistical significance was
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a doubling of thromboembolism. The absolute
increased risk of this morbidity varied with age
and other thrombotic risk factors from one in 10
000 in a healthy woman aged 50 years up to
one in 100 in a woman aged 80 years. Overall,
between the ages of 50 and 79 the annual
increase in stroke was around one per 1000
women treated, but the absolute risk was low
in the 50s and increased with age. A trend to an
increased risk in cardiovascular disease was
seen only in the cHT arm of the WHI and was
significantly raised only in those initiating cHT
over 70 years of age.
In the cHT arm of the WHI, an increase in
breast cancer was seen by 5 years of eight per
10 000 (<0.1%) per year. This was matched by
a similar reduction in other major cancers
(Figure 2). In the WHI study there were no
changes in overall cancer and mortality rates.30
In 2004, the ET arm of the WHI study ceased
after 6.8 years showing a reduction in breast
cancer of seven per 10 000 per year (Figure 3).31
This suggests a different risk profile to com-
bined therapy for women without a uterus and
on this oestrogen only regimen. Again the
absolute risk for vascular disease rose with age. 
A long term trial of HT from early
menopause would be required to see if there is
any primary neuro- or cardio-protective effect;
but following the WHI cannot be recommended
for these indications. The risks of HT do appear
to be greater when initiated in later age, espe-
cially if there is established arterial disease.
However, to date the data from randomised
controlled trials, observational, animal and labo-
ratory studies suggest a better risk/benefit
profile when HT is used from around the time
of menopause. Thus, HT is an option for the
prevention of osteoporotic fractures particularly
in the at risk symptomatic woman around early
menopause. 
Ideally, oestrogen therapy should be contin-
uous (ie. without a break in therapy). Adjuvant
progestogens are necessary in women who
still have a uterus to protect against endome-
trial cancer. They may be given cyclically for
10–14 days each month in perimenopausal
women or as continuous therapy combined
with oestrogen in postmenopausal women.
The latter is more suitable for women more
than 2 years postmenopause to avoid the initial
irregular bleeding normally seen with this
regimen being unduly prolonged.
As with all therapies, women should be fully
informed of the risks and benefits of their par-
ticular HT regimen, be reviewed annually, and
therapy should be individualised. The optimal
dose of HT required to prevent bone loss may
vary from woman to woman. With any therapy
for osteoporosis, repeat bone density should be
considered after 2 years to check the therapeu-
tic regimen is efficacious. 
Tibolone
Tibolone is an alternative to oestrogen therapy
and its effect on BMD appears to be similar.32
There are currently no antifracture data avail-
able, but an ongoing randomised controlled trial
(LIFT) has vertebral fracture as a primary
outcome. It is unclear whether the concerns
raised about other endpoints from the WHI
apply to tibolone.
Calcium
Calcium is weakly antiresorptive and supple-
mentation may reduce negative calcium
balance, particularly in older age. Most studies
suggest the required daily intake is between
1000 mg and 1500 mg in postmenopausal
women not taking oestrogen replacement
therapy. This can be obtained from about three
serves of dairy products per day. For example,
one glass (250 mL) of milk, two slices (40 g) of
cheddar cheese, or one tub (200 g) of yoghurt
each contains about 300 mg of calcium. For
those who are unable to tolerate dairy products,
calcium enriched soy milk and a large variety of
calcium supplements are currently available
from pharmacies and health food stores.
However, patients need to understand the
varying calcium content of different supple-
ments and that the recommended daily intake
relates to elemental calcium. Controlled trials
have found small effects of calcium supplemen-
tation on bone density averaging 1–2%
associated with a modest reduction in fracture
risk in some studies.33,34
In patients using bisphosphonates, calcium
must not be taken at the same time of day as
the bisphosphonate or the calcium will impair
absorption of the drug. Calcium carbonate may
also cause mild constipation or upper gastroin-
testinal upset. Calcium citrate is now available
in Australia as an option for these patients.
Calcium supplements should be avoided in
patients with a history of renal calculi in the
presence of hypercalcinuria. 
Vitamin D 
Vitamin D undergoes metabolism in the liver
and kidney. Simple vitamin D is mainly available
in Australia as ergocalciferol (Ostelin 1000 IU
per capsule) or cod liver oil tablets (approxi-
mately 400 IU). Smaller amounts of vitamin D
are also contained in some calcium and vitamin
supplements (eg. Caltrate + D contains 200 IU
per tablet). These preparations are beneficial for
preventing vitamin D deficiency in individuals
with a poor diet or limited sunlight exposure.
However, patients presenting with moderate to
severe vitamin D deficiency (serum 25 hydrox-
yvitamin D <30 nmol/L) are at high risk for
osteomalacia and hip fractures and require long
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Figure 3. Annual disease risk after 7 years of
oestrogen only HT31
term high dosage vitamin D supplementation
(up to Ostelin 2000–5000 IU/day). In Australia,
these population groups include the house-
bound elderly, older women in residential care
facilities, dark skinned or veiled women, and
individuals with malabsorption.35
The role of supplemental vitamin D for pre-
venting fractures has been demonstrated in a
number of studies. In one French study
involving vitamin D deficient institutionalised
elderly patients, simple vitamin D3 (800 IU)
and calcium (1200 mg/day) reduced hip frac-
tures by 43%.36 In a recent British study
involving elderly community dwelling men
and women, cholecalciferol 100 000 units
administered orally every 4 months for 5
years resulted in a 35% reduction in all major
osteoporotic fractures.37
Calcitriol
Calcitriol (active vitamin D metabolite) has a
therapeutic profile distinct from vitamin D and
should not be used in the treatment of vitamin
D deficiency.6 Calcitriol is available on the PBS
(Authority required) for the treatment of post-
menopausal osteoporosis in Australia. The
evidence on efficacy in fracture prevention is
confusing, with studies showing both increased
and deceased numbers of fractures. Calcitriol
should not be used as a sole therapy for the
treatment of osteoporosis.
Parathyroid hormone
Parathyroid hormone (PTH) stimulates osteo-
clasts and osteoblasts in the bone, but when
presented to bone intermittently such as in
daily subcutaneous administration, it has a net
anabolic action. It increases cancellous bone
mass by about 15–20% over 3 years and
reduces the relative risk of vertebral fractures
by up to 65% in women with osteoporosis and
one or more baseline fractures as well as
peripheral fractures. It is now registered in
Australia as an 18 month therapeutic course
but as yet is not PBS listed. In view of its cost,
it is anticipated that PTH will become a treat-
ment option for individuals with severe
osteoporosis with ongoing fractures who have
failed other therapies.38
Strontium ranelate 
Strontium ranelate has been shown in clinical
trials to reduce the risk of both vertebral and
peripheral fractures. In the 3 year TROPOS
study, a 41% reduction in vertebral fractures
(relative risk 0.59; 95% confidence interval,
0.48–0.73) associated with an increase in
lumbar spine and femoral neck BMD
occurred.39 The exact mechanism of action of
strontium is unclear, but an antiresorptive
action has been described. This agent is cur-
rently unavailable in Australia.
Thiazide 
Several large, prospective epidemiological
studies in elderly men and women have
shown that thiazide use is associated with a
reduced risk of hip fracture. Several possible
mechanisms could explain this association.
Thiazides act directly on the distal nephron to
enhance calcium reabsorption leading to posi-
tive calcium balance. Thiazides may also
reduce osteoclastic activity possibly by inhibit-
ing carbonic anhydrase. One randomised
study of treatment of systolic hypertension
included bone mass as a secondary endpoint
in a subset of patients. The subjects who took
thiazide had increased bone mass whereas
those on other forms of antihypertensive
medication showed a decrease in bone
mass.40 The effect of thiazides on bone
density in patients with normal blood pres-
sure has not been studied, but a randomised
trial is underway.
Combination therapy 
While there are published data demonstrating
an additive effect of combination therapies on
BMD, there are no published data regarding
additional antifracture benefit and the role of
combination therapy is unclear.41
Monitoring therapy
Patient education is essential for treatment
adherence. This includes information on their
disease as well as the importance of interven-
tion therapies. This should be tailored to
address individual patient concerns about the
specific risks of their treatment. 
After therapy has been initiated, it is impor-
tant to monitor patients to ensure that bone
loss is controlled. Bone densitometry using
DEXA measurements can be used for monitor-
ing the efficacy of therapy because of their
precision; they can be performed rapidly and
conveniently. It should be noted that changes
of less than 5% are within the measurement
error of most machines and therefore should be
regarded as representing no significant change.
It is often recommended that a repeat DEXA be
performed within 1 year of starting osteoporo-
sis treatment, especially in the case of
corticosteroid induced osteoporosis. For other
patients, measurement at 2 years is likely to
reflect more accurately the effect of an antire-
sorptive drug. Thereafter, biennial DEXA
assessments are usually carried out to monitor
response to therapy. Repeat measurements
should generally be performed on the same
machine for monitoring, assuming the DEXA
provider has good quality control with accept-
able precision error. Biochemical measures of
bone turnover may become useful in the man-
agement of the individual patient, but their role
has yet to be established. In certain cases, 
specialist referral may be able to fine tune
therapy (Table 4).
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Table 4. When to consider referral to a specialist
• Problems or side effects with treatment
• Other complex medical conditions
• No access to appropriate bone densitometry
• Inadequate response to therapy
• A vertebral fracture (a one visit assessment by a specialist is prudent)
• Young patient (age <50) with osteoporosis
• Secondary cause is identified
• Continued fractures with ‘normal’ bone densitometry
Prevention of fragility fractures
Preventing falls
Interventions to reduce the risk of falling
include:
• modifying the environment to reduce the risk
of slipping and tripping by eliminating slip-
pery surfaces, loose rugs, narrow
passageways, dangerous furniture. Most
people report trips, slips and loss of balance
as the cause of the fall, whereas only a small
proportion report dizziness or feeling faint
• modifying living habits:
– by wearing appropriate footwear
– taking care when walking up or down 
steps, especially if wearing bifocals
– taking care at night and in poorly lit condi-
tions
• installing appropriate aids (eg. supportive
handrests, rails and nonslip bathmats)
• modifying medications (eg. sedatives, anti-
depressants or certain antihypertensives
that might predispose patients to falls)
• correcting poor vision, and 
• involving community agencies to:
– provide support services to help imple
ment the modifications required to reduce
the risk of injury
– ensuring nursing and physiotherapy services
are provided when needed.
Specific exercise programs that emphasise
ground reaction forces, muscle strengthening
and balance retraining (eg. tai chi, resistance
training or high impact exercise) may also be
effective. Aerobic training, water exercises,
and flexibility/calesthenics have not been
shown to be effective forms of exercise for
falls prevention.42,43
Preventing osteoporosis
Although medical intervention may be
required in some individuals, patients should
understand that it is important to:
• maximise peak bone density in childhood
and adolescence, and
• maintain bone density throughout adult life.
Osteoporosis prevention programs should:
• promote a diet with adequate calcium and
advocate regular weight bearing high
impact, and/or strengthening exercise in chil-
dren and adolescents
• exercise in premenopausal women should
include resistance training to improve
muscle mass, strength and balance, as well
as regular weight bearing high impact,
and/or strengthening exercises
• exercise in postmenopausal women should
include resistance training to improve
muscle mass, strength and balance, as well
as specific balance training which should be
performed three times per week6
• encourage good general nutrition and
ensure vitamin D status is maintained, espe-
cially in elderly patients, and 
• discourage tobacco use.
Conclusion
The management of postmenopausal osteo-
porosis should be based on an individual
risk/benefit analysis, time since menopause,
presence or absence of oestrogen with-
drawal symptoms, history of atraumatic
fractures, and other medical conditions.
Oestrogen therapy remains appropriate for
women at the time of menopause for those
with symptoms, and for those with prema-
ture or surgical menopause. The duration of
use should be reviewed at 2–5 years. 
Raloxifene and bisphosphonates are alter-
natives for prevention of bone loss after
menopause when symptoms of oestrogen
withdrawal are no longer a consideration;
although their use in this fashion before a
fracture is currently not subsidised by the
PBS. In older women, especially those with a
prior osteoporotic fracture and high risk of
further fracture, bisphosphonates should be
considered as first line therapy because they
reduce the risk of both nonvertebral and ver-
tebral fractures. Vitamin D deficiency should
be excluded before initiation of treatment. All
women should have an adequate calcium
intake of at least 1000 mg per day. Simple
vitamin D (with calcium) supplementation
should be considered in those groups at risk
of vitamin D deficiency and osteomalacia,
either as monotherapy or in combination with
other treatments.
Summary of important points
• The cause of osteoporosis should be identi-
fied and specific disease processes should
be treated appropriately.
• Whereas primary prevention of fracture
remains crucial, treatment to ensure that
further fractures do not occur is equally 
as important.
• Any patient aged 45 years and older pre-
senting with a low trauma fracture should
undergo bone densitometry (Medicare
rebate available for these patients). 
• Women at high risk of osteoporosis (Table
1, 2) should undergo DEXA for diagnosis
(Table 2 attracts a Medicare rebate). 
• The role of long term oestrogen as first line
therapy to prevent bone loss at the time of
menopause is controversial. The potential
benefits must be rationally considered and
discussed with patients balanced against
the possible small increase in the risk of
breast cancer. 
• In older patients with prior fractures, first
line treatments are alendronate or rise-
dronate. Raloxifene is an alternative first line
treatment to prevent spinal fractures. 
• Simple vitamin D supplementation should
be considered in the housebound or institu-
tionalised elderly. 
• Adequate dietary calcium and a lifestyle that
includes the correct modality of exercise
and falls prevention are also important. 
Acknowledgment
This article was developed by the Osteoporosis
Australia Medical Scientific Committee.
Resources
Osteoporosis Australia (www.osteoporosis.
org.au) has a range of education materials
available for patients and health care profes-
sionals covering different aspects of
osteoporosis and its management. There are
regular courses on osteoporosis and self man-
agement teaching people how to maintain
bone mass, how to avoid falls and fractures,
and how to live more comfortably with osteo-
porosis. Helpline 1800 242 141. 
Australian and New Zealand Bone and Mineral
Society (www.anzbms.org.au).
916Reprinted from Australian Family Physician Vol. 33, No. 11, November 2004
Clinical practice: Guidelines for the management of postmenopausal osteoporosis for GPs
Conflict of interest: none declared.
References 
1. NIH Consensus Development Panel on
Osteoporosis Prevention, Diagnosis, and Therapy.
Osteoporosis prevention, diagnosis, and therapy.
JAMA 2001;285:785–795.
2. The burden of brittle bones: costing osteoporosis
in Australia. Canberra: Access Economics, 2001.
3. Sanders KM, Nicholson GC, Ugoni AM, Pasco JA,
Seeman E, Kotowicz MA. Health burden of hip and
other fractures in Australia beyond 2000. Med J
Aust 1999;170:467–470.
4. Jiang G, Eastell R, Barrington NA, Ferrar L.
Comparison of methods for visual identification of
prevalent vertebral fracture in osteoporosis.
Osteoporosis Inter 2004;4:8.
5. Schneider DL, von Muhlen D, Barrett-Connor E, et
al. Kyphosis does not equal vertebral fractures: the
Rancho Bernardo study. J Rheumatol
2004;31:747–752.
6. Writing group for Osteoporosis Australia and the
National Prescribing Service. Preventing osteoporo-
sis: outcomes of the Australian Fracture Prevention
Summit. Med J Aust 2002;176(Suppl). 
7. Marshall D, Johnell O, Wedel H. Meta-analysis of
how well measures of bone mineral density predict
occurrence of osteoporotic fractures. BMJ
1996;312:1254–1259.
8. Henry MJ, Pasco JA, Seeman E, Nicholson GC,
Sanders KM, Kotowicz MA. Geelong Osteoporosis
Study. Assessment of fracture risk: value of random
population based samples – the Geelong
Osteoporosis Study. J Clin Densitom
2001;4:283–289. 
9. Garnero P, Hausherrt E, Chapuy MC, et al. Markers
of bone resorption predict hip fracture in elderly
women. The EPIDOS prospective study. J Bone
Min Res 1996;11:1531–1537.
10. Eastell R, Barton I, Hannon RA, Chines A, Garnero
P, Delmas PD. Relationship of early changes in
bone resorption to the reduction in fracture risk
with risedronate. J Bone Miner Res
2003;18:1051–1056.
11. Fiatarone Singh MA. Physical activity and bone
health. Aust Fam Physician 2004;33:125.
12. McClung M, Clemmesen B, Daifotis A, et al.
Alendronate prevents postmenopausal bone loss in
women without osteoporosis. Ann Int Med
1998;128:253–261.
13. Delmas PD, Bjarnason BH, Mitlak NH, et al. Effect
of raloxifene on bone mineral density, serum cho-
lesterol and uterine endometrium in
postmenopausal women. N Engl J Med
1997;337:1641–1647. 
14. Gallagher J C, Baylink D J , Freeman R, McLung M.
Prevention of bone loss with tibolone in post-
menopausal women: results of two randomised,
double blind, placebo controlled, dose finding
studies. J Clin Endocrinol Metab
2001;86:4717–4726.
15. Writing group for the PEPI trial. Effects of hormone
therapy on bone mineral density. JAMA
1996;276:1389–1396.
16. Liberman UA, Weiss SR, Broll J, et al. Effect of oral
alendronate on bone mineral density and the inci-
dence of fractures in postmenopausal
osteoporosis. N Engl J Med 1995;333:1437–1443.
17. Black D M, Cummings S R, Karpf D, et al.
Randomised trial of effect of alendronate on risk of
fracture in women with existing vertebral frac-
tures. Lancet 1996;348:1535–1541.
18. Harris ST, Watts NB, Fenant HK, et al. Effects of rise-
dronate treatment on vertebral and nonvertebral
fractures in women with established osteoporosis.
JAMA 1999;282:1433–1452.
19. Reginster JY, Minne HW, Sorensen OH, et al.
Randomised trial of the effects of risedronate on
vertebral fractures in women with established post-
menopausal osteoporosis. Osteoporos Int
2000;11:83–91.
20. Cummings SR, Black DM, Thompson DE, et al.
Effect of alendronate on risk of fracture in women
with low bone density but without vertebral frac-
tures. JAMA 1998;280:2077–2082.
21. McClung MR, Geusens P, Miller PD, et al. Effects of
risedronate on the risk of hip fracture in elderly
women. New Engl J Med 2001;344:333–340. 
22. Australian Adverse Drug Reactions Bulletin. A gut
feeling for alendronate. Canberra: AIHW
1999;3:11,18.
23. Storm T, Thamsborg G, Steiniche T, Genant HK,
Sorenson OH. Effect of intermittent cyclical
etidronate therapy on bone mass and fracture rate
in postmenopausal osteoporosis. N Engl J Med
1990;322:1265–1271.
24. Bone HG, Hosking D, Devogelaer JP. Ten years
experience with alendronate for osteoporosis in
postmenopausal women. New Engl J Med
2004;350:1189–1199.
25. Sornay-Rendu E, Garnero P, Munoz F, et al. Effect of
withdrawal of hormone replacement therapy on
bone mass and bone turnover: the OFELY study.
Bone 2003;33:159–166.
26. Cauley JA, Norton L, Lippman ME, et al. Continued
breast cancer risk reduction in postmenopausal
women treated with raloxifene: 4 year results from
the MORE trial. Breast Cancer Res Treat
2001;65:125–134.
27. Ettinger B, Black DM, Mitlak BH, et al. Reduction of
vertebral fracture risk in postmenopausal women
with osteoporosis treated with raloxifene: results
from a 3 year randomised controlled trial. JAMA
1999;282:637–645.
28. Delmas PD, Genant HK, Crans GG, Stock JL, Wong
M, Siris E, Adachi JD. Severity of prevalent vertebral
fractures and the risk of subsequent vertebral and
nonvertebral fractures: results from the MORE trial.
Bone 2003;33:522–532.
29. Kanis JA, Johnell O, Black DM, et al. Effect of ralox-
ifene on the risk of new vertebral fracture in
postmenopausal women with osteopenia or osteo-
porosis: a reanalysis of the Multiple Outcomes of
Raloxifene Evaluation trial. Bone 2003;33:293–300.
30. Writing group for the Women’s Health Initiative
Investigators. Risks and benefits of oestrogen plus
progestin in health postmenopausal women. JAMA
2002;3:321–330.
31. Writing group for the Women’s Health Initiative
Investigators. Effects of conjugated equine oestro-
gen in postmenopausal women with hysterectomy:
the Women’s Health Initiative randomised con-
trolled trial. JAMA 2004;291:1701–1712.
32. Hannover N, Bjarnason K, Haarbo J, Rosenquist C,
Christiansen C. Tibolone: prevention of bone loss in
late postmenopausal women. J Clin Endocr Metab
1996;81:2419–2423.
33. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe
SJ. Effect of calcium supplementation on bone loss
in postmenopausal women. N Engl J Med
1993;328:460–464.
34. Dawson Hughes B, Harris S, Krall EA, Dallal GE.
Effect of calcium and vitamin D supplementation
on bone density in men and women 65 years of age
or older. N Engl J Med 1997;337:670–676.
35. Nowson CA, Diamond TH, Pasco JA, Mason RS,
Sambrook PN, Eisman JA. Vitamin D in Australia.
Issues and recommendations. Aust Fam Physician
2004;33:133–138.
36. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3
and calcium to prevent hip fractures in elderly
women. N Engl J Med 1993;327:1637–1642.
37. Trivedi DP, Doll R, Tee Khaw K. Effect of oral four
monthly vitamin D3 (cholecalciferol) supplementa-
tion on fractures and mortality in men and women
living in the community: randomised double blind
controlled trial. BMJ 2003;326:469–474.
38. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of
parathyroid hormone (1–34) on fractures and bone
mineral density in postmenopausal women with
osteoporosis. N Engl J Med 2001;344:1431–1441.
39. Meunier PJ, Roux C, Seeman E, et al. The Effects of
strontium ranelate on the risk of vertebral fracture
in women with postmenopausal osteoporosis. N
Engl J Med 2004;350:504–506.
40. Schoofs MWCJ, Van der Klift M, Hofman A, et al.
Thiazide diuretics and the risk for hip fracture. Ann
Intern Med 2003;139:476–482.
41. Additive effects of raloxifene and alendronate on
bone density and biochemical markers of bone
remodelling in postmenopausal women with
osteoporosis. J Clin Endocrinol Metab
2002;87:985–992.
42. Gillespie LD, Gillespie WJ, Robertson MC, Lamb
SE, Cumming RG, Rowe BH. Interventions for pre-
venting falls in elderly people (Cochrane Review).
In: The Cochrane Library, Issue 4, 2001. Oxford:
Update Software.
43. Forwood MR, Larsen JA. Exercise recommenda-
tions for osteoporosis. A position statement of the
Australian and New Zealand Bone and Mineral
Society. Aust Fam Physician 2000;29:761–764.
Clinical practice: Guidelines for the management of postmenopausal osteoporosis for GPs
Reprinted from Australian Family Physician Vol. 33, No. 11, November 2004 917
Correspondence
Email: s.oneill@uq.edu.au
AFP
